share_log

Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $95

Benzinga ·  Apr 25 08:51

Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $100 to $95.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment